PDF(1033 KB)
Advances in the role of miR-378a in skeletal muscle development and diseases
Zi-Ting DING, Dan LAN
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (4) : 522-528.
PDF(1033 KB)
PDF(1033 KB)
Advances in the role of miR-378a in skeletal muscle development and diseases
MicroRNAs (miRNAs) are endogenous noncoding RNAs involved in post-transcriptional regulation. miR-378a is highly expressed in skeletal muscle and plays important roles in myogenesis, maintenance of muscle homeostasis, and disease progression. Studies indicate that miR-378a participates in myogenic differentiation, energy metabolism, and muscle fiber-type switching by regulating molecules such as histone deacetylase 4 and mitogen-activated protein kinase 1. Dysregulated miR-378a is associated with muscle diseases: in Duchenne muscular dystrophy, its expression level negatively correlates with disease severity, and overexpression can ameliorate disease phenotypes; in limb-girdle muscular dystrophy type 3, rhabdomyosarcoma, sarcopenia, and spinal muscular atrophy, its potential value as a biomarker or therapeutic target has attracted increasing attention. This review summarizes the molecular characteristics of miR-378a and its roles in skeletal muscle development and related diseases, providing a reference for clinical translation.
Muscle disease / miR-378a / Skeletal myogenesis / Biomarker / Therapeutic target
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
姚一龙. LncRNA-MEG3介导microRNA-133a/378a调控骨骼肌再生和肌纤维类型转化的机制[D]. 北京: 中国农业科学院, 2022.
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
《中国肢带型肌营养不良携带者筛查专家共识》制订组. 中国肢带型肌营养不良携带者筛查专家共识[J]. 国际神经病学神经外科学杂志, 2024, 51(5): 61-67. DOI: 10.16636/j.cnki.jinn.1673-2642.2024.05.008 .
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
所有作者均声明无利益冲突。